Federal regulators declined to approve a nasal spray from a San Diego company to treat severe allergic reactions late Tuesday, calling for more research on what would have been the first alternative to injections using devices such as an EpiPen. A Raleigh firm also has a nasal spray alternative under development.
Read More
The company is working towards FDA approval of its epinephrine nasal spray, named UTULY, for treating anaphylaxis. If successful, it may replace the current anaphylaxis treatment standard, which is the needle-based EPIPEN.
Read More
Bryn Pharma, a privately held pharmaceutical company focused on creating a new treatment for anaphylaxis – a life-threatening allergic reaction – not only has a new CEO and COO but also $15 million in cash as the company seeks FDA approval for its unique nasal spray.
Read More
Bryn Pharma has appointed a new Chief Operating Officer, the company announced this week. This announcement comes just two weeks after the Raleigh-based startup named a new CEO.
Read More
Bryn Pharma names pharmaceutical industry veteran Sandy Loreaux as the new CEO, with hopes she has the commercialization experience to advance their Epi-Pen alternative.
Read More
First disclosed in a recent SEC filing, Raleigh startup Bryn Pharma on Tuesday confirmed its latest funding news – $11 million.
Read More
Many investors have a great deal of confidence in Bryn Pharma, a Raleigh-based pharmaceutical company that is developing an epinephrine nasal spray to treat anaphylaxis.
Read More
Investors continue to pour money into Bryn Pharma, the Raleigh-based startup developing an alternative to the EpiPen. Here’s an update.
Read More
An estimated 49 million Americans are at risk for anaphylaxis. Anaphylaxis is a severe overreaction of the body’s immune system to a foreign substance to which the body has become sensitized. It’s often caused by foods such as peanuts, insect stings, some medications and latex.
Read More
